Percheron Therapeutics LimitedASX: PER

ATL1102 for MS Phase IIb Investigational New Drug Submission

Apr 24, 2017 at 3:20 AM UTC · Issued by Percheron Therapeutics Limited

Percheron Therapeutics Limited has released a press release.

View Attachment